Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Clover Bio Starts China Phase III Trial of Enbrel Biosimilar

publication date: Dec 30, 2019

Clover Biopharma of Chengdu dosed the first patient in a China Phase III trial of SCB-808, an Enbrel® (etanercept) biosimilar, for patients with rheumatic diseases, including ankylosing spondylitis and rheumatoid arthritis. Clover is developing SCB-808 in a prefilled syringe formulation, unlike the powder formulations of Embrel biosimilars currently approved in China. Also, the company's candidate is being tested under new China guidelines for biosimilars, which require head-to-head comparisons with the original drug. Formed in 2016, Clover develops novel biologics, using its trimer-tag technology, along with biosimilars. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital